CALGB40502_2D | R Documentation |
Kaplan-Meier digitized data from CALGB40502, figure 2D (PMID 26056183). A reported sample size of 799 for a primary endpoint of PFS in breast cancer.
CALGB40502_2D
A data frame of 542 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (nab_paclitaxel, p1) | |
Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33: 2361–9.
summary(CALGB40502_2D)
kmplot(CALGB40502_2D)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.